Efficacy of the bacterial lysate as a means of preventing COPD exacerbations in patients with different histories of previous exacerbations
https://doi.org/10.21626/vestnik/2017-1/08
Abstract
The purpose of the study was to estimate the efficiency of oral bacterial lysate OM-85 as a means of preventing COPD exacerbations and related hospitalizations in patients varying in initial frequency of exacerbations of the disease. The retrospective cohort study included 94 in-patients whose previous hospitalization for COPD exacerbations were carried out in the same health facility. 18 follow-ups had received one or more courses of treatment with OM-85 since the previous hospitalization. The efficacy of OM-85 was evaluated in two clusters of patients comparable in volume with different history of previous COPD exacerbations: <2 times a year and ≥ 2 times a year. It was established that OM-85 prolongs the stable course of COPD, and defers the need for next hospitalization for COPD exacerbations almost equally in both clusters of patients.
About the Authors
I. N. Chelenkova
Scientific Center for Medical Commodities Expertise
Russian Federation
Russian Federation
N. D. Bunyatyan
Scientific Center for Medical Commodities Expertise
Russian Federation
Russian Federation
I. Yu. Trofimenko
Reutov Central City Clinical Hospital
Russian Federation
Russian Federation
References
1. Авдеев С.Н. Значение обострений для пациентов с ХОБЛ // Эффективная фармакотерапия. Пульмонология и оториноларингология. - 2014. - № 2 (29). - С. 36-41.
2. Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения // Пульмонология. - 2013. - № 3. - С. 5-19.
3. Бунятян Н.Д., Утешев Д.Б., Корсун Л.В., Челенкова И.Н. Фармакоэпидемиологическое и фармакоэкономическое исследование лекарственного лечения больных ХОБЛ // Ведомости научного центра экспертизы средств медицинского применения. - 2011. - № 2. - С. 60-61.
4. Калюжин О.В., Челенкова И.Н., Понежева Ж.Б. Влияние респираторных вирусов на течение хронической обструктивной болезни легких: на пути к оптимизации лечения // Терапевтический архив. - 2015. - Т. 87, № 3. - С. 98-104.
5. Челенкова И.Н., Бунятян Н.Д., Трофименко И.Ю. Влияние перорального бактериального лизата на продолжительность ремиссии ХОБЛ: фармакоэпидемиологическое исследование // Ремедиум. Журнал о российском рынке лекарств и медицинской технике. - 2015. - № 4. - С. 49-52.
6. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких // Русс. мед. журн. - 2014. - № 5. - С. 331-347.
7. Braido F., Tarantini F., Ghiglione V., Melioli G., Canonica G.W. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections // Int. J. Chron. Obstruct. Pulmon. Dis. - 2007. - Vol. 2, N 3. - P. 335-345.
8. Cazzola M., Anapurapu S., Page C.P. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis // Pulm. Pharmacol. Ther. - 2012. - Vol. 25, N 1. - P. 62-68. - doi: 10.1016/j.pupt.2011.11.002.
9. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (Updated 2016). Global Initiative for Chronic Obstructive Lung Disease, Inc; 2016.
10. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F., Wedzicha J.A. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease // N. Engl. J. Med. - 2010. - Vol. 363, N 12. - P. 1128-1138. - doi: 10.1056/NEJMoa0909883.
11. Koatz A.M., Coe N.A., Cicerán A., Alter A.J. Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections // Lung. - 2016. - Vol. 194, N 4. - P. 687-697. - doi: 10.1007/s00408-016-9880-5.
12. Pan L, Jiang XG, Guo J, Tian Y, Liu C.T. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis // J. Clin. Pharmacol. - 2015. - Vol. 55, N 10. - P. 1086-1092. - doi: 10.1002/jcph.518.
13. Sprenkle M.D., Niewoehner D.E., MacDonald R., Rutks I., Wilt T.J. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review // COPD. - 2005. - Vol. 2, N 1. - P. 167-175.
14. Steurer-Stey C., Bachmann L.M., Steurer J., Tramèr M.R. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review // Chest. - 2004. - Vol. 126, N 5. - P. 1645-1655.
Review
For citations:
Chelenkova I.N., Bunyatyan N.D., Trofimenko I.Yu. Efficacy of the bacterial lysate as a means of preventing COPD exacerbations in patients with different histories of previous exacerbations. Kursk Scientific and Practical Bulletin "Man and His Health". 2017;(1):46-50. (In Russ.) https://doi.org/10.21626/vestnik/2017-1/08
Views:
620
Email this article 